Rakuyaku AI, Specialized in Pharmaceutical Documents, Declares Full Transition to AI-Driven Organization

Rosetta, Inc., a member of the Metareal Group that develops and provides 'Rakuyaku AI,' an AI specialized in pharmaceutical documents, announced today, June 1, 2026, that Rakuyaku AI has declared a full transition to an AI-driven organization centered on Claude Code. This is positioned as an 'irreversible structural transformation' where all intellectual labor is entrusted to AI as the 'execution layer,' and humans focus on instructions and judgment, rather than just introducing tools. As a leader in AI transformation in the pharmaceutical industry, by becoming the organization most deeply immersed in AI, we embody persuasiveness and transformation promotion power for our clients. The use of generative AI is rapidly evolving from the stage of 'asking ChatGPT questions' to the stage of 'AI autonomously executing tasks.' Achievements in the pharmaceutical field are also beginning to emerge; in April 2026, our pharmaceutical document-specialized generative AI 'Rakuyaku AI' succeeded in shortening the draft creation period for CSR (Clinical Study Reports) by more than 90%, from about four weeks to about two days. We expect to reduce the overall development process workload by 50-60%, and even in the pharmaceutical industry, where regulatory requirements are extremely strict, the use of AI as an 'execution layer' is achieving certain results. We stand at the forefront of AI utilization and use our own business transformation to provide persuasiveness for proposals to pharmaceutical companies.